An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities

  Measured over: From first dose and within 135 days after last dose of study therapy (Up to approximately 82 months)

• Part C, D1, D2, E - Objective Response Rate Per BICR

  Measured over: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

• Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR

  Measured over: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

• Part C, D1, D2, E - Duration of Response (DOR) Per BICR

  Measured over: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

• Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy

  Measured over: From first dose and within 2 days of first dose of study therapy

• Part C, D1, D2, E - Objective Response Rate Per BICR

  Measured over: From first dose (Day 1) and up to 97 months

Changes Tremor has spotted